Moderna

NASDAQ: MRNA

Stock price

248.69 USD

(+0%) TODAY

Earnings Call Takeaways

Call date: Nov 6, 2026

1) Financial Performance Highlights
- Generated $1.4 billion in revenues for Q3 2026, reflecting a 29% YoY growth.
- Achieved a net income of $200 million for the quarter, with cash and investments totaling $8 billion.
- Reduced cash costs by 10% compared to Q3 2025, with R&D expenses down 27% to $583 million.
- Increased full-year revenue guidance to 15% - 25% growth, up from a previous forecast of up to 10%.

2) Product and Pipeline Updates
- Received FDA approval for mFLUSIVA, marking it as the first mRNA-based influenza vaccine.
- Positive Phase 3 results for Intismeran, showing a 42% reduction in recurrence or death risk in melanoma patients.
- Advancements in oncology and rare diseases, with ongoing studies in non-small cell lung cancer and propionic acidemia.
- Secured approvals for mCOMBRIAX in Canada and continued progress in international markets for respiratory vaccines.

3) Strategic Initiatives and Leadership
- Strengthened financial position through a $3 billion convertible note issuance, netting approximately $2.6 billion.
- Welcomed back Juan Andres to the executive committee, enhancing leadership in manufacturing and operational strategy.
- Focus on geographic and portfolio expansion as key drivers for future growth, particularly in oncology and respiratory vaccines.

4) Challenges and Market Dynamics
- Increased cost of sales by 54% YoY due to higher product sales volume and manufacturing costs.
- Ongoing discussions regarding the regulatory pathway for the mRNA-1.08 thousand COVID-flu combination vaccine in the U.S.
- The Phase 3 study for the norovirus vaccine did not meet statistical criteria for early success, prompting a reevaluation of the program.

5) Outlook and Guidance
- The company anticipates continued revenue growth driven by strong demand for respiratory vaccines and strategic partnerships.
- Guidance for cash and investments at year-end 2026 is projected between $8.1 billion and $8.3 billion.
- Upcoming milestones include the submission of the Intismeran BLA and further updates on ongoing clinical trials in oncology.

Bottom line: Moderna's strong Q3 performance, highlighted by significant revenue growth and strategic advancements in its product pipeline, positions the company favorably for continued expansion and innovation in the biotech sector. Investors should be optimistic about the company's ability to leverage its mRNA technology across multiple therapeutic areas while maintaining financial discipline.

Moderna (MRNA) earnings call summaries

Read Moderna (MRNA) quarterly earnings call takeaways covering reported results, management commentary, business priorities, guidance, and material risks.

Compare recent calls to follow changes in management expectations and connect qualitative updates with the company’s fundamental performance.